سعر بوليفي 140 مجم فيال وريدي 2026

Polatuzumab vedotin 140 mg lyophilised powder vial for intravenous infusion (Roche), a CD79b-directed antibody-drug conjugate for diffuse large B-cell lymphoma.

• With rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP) for adults with previously untreated DLBCL NOS or HGBL with IPI score >= 2Population: AdultsDailyMed (US NLM)
• With bendamustine and a rituximab product for adults with relapsed or refractory DLBCL NOS after at least two prior therapiesPopulation: AdultsDailyMed (US NLM)

• None listed in the US label.International label, same product · DailyMed (US NLM)

• Peripheral neuropathy, including severe cases; cumulative and may exacerbate pre-existing neuropathy.International label, same product · DailyMed (US NLM)
• Infusion-related reactions, including delayed reactions up to 24 hours.International label, same product · DailyMed (US NLM)
• Serious or severe myelosuppression (neutropenia, febrile neutropenia, thrombocytopenia, anaemia).International label, same product · DailyMed (US NLM)

• Advise women not to breastfeed.International label, same product · DailyMed (US NLM)

• Polatuzumab vedotin: Antibody-drug conjugate targeting CD79b on B cells; releases the microtubule inhibitor MMAE inside the cell.